EMEA-003392-PIP01-23 - paediatric investigation plan
broadly neutralizing anti-HIV human monoclonal antibody (VH3810109)
PIPHuman
Key facts
- Active Substance
- broadly neutralizing anti-HIV human monoclonal antibody (VH3810109)
- Therapeutic area
- Infections and infestations
- Decision number
- P/0505/2023
- PIP number
- EMEA-003392-PIP01-23
- Pharmaceutical form(s)
- Powder for solution for injection/infusion
- Condition(s) / indication(s)
- Treatment of human immunodeficiency virus (HIV-1) infection
- Route(s) of administration
- Subcutaneous use
- Intravenous use
- Contact for public enquiries
ViiV Healthcare UK Limited
E-mail: eu.paediatric-plans@gsk.com
Tel: +1 4388998201- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date